|
|
|
|
Document Preview Agreement |
||||
|
|
||||
|
Click "Add to Cart" button to purchase document. |
||||
|
|
||||
|
Title: |
Agreement |
|||
|
Entities: |
CollaGenex Pharmaceuticals Inc.; Taisho Pharmaceutical Co., Ltd. |
|||
|
Date: |
2002 |
|||
|
Size: |
Preview shows 13KB of 114KB total |
|||
|
Price: |
$62 |
|||
|
ID: |
#284078 |
|||
|
|
||||
|
||||
|
|
||||
|
Start of Preview |
||||
AGREEMENT
between
ALTANA INC.
and
COLLAGENEX PHARMACEUTICALS, INC.
May 24, 2002
{PAGE}
TABLE OF CONTENTS
PAGE
Article I DEFINITIONS 1
Article II LICENSE GRANTS 6
Section 2.01. Exclusive License Grant.................................6
Section 2.02. Non-Exclusive License Grant.............................6
Section 2.03. Disclosure of Information...............................6
Section 2.04. Extension of Patent Life................................7
Section 2.05. Improvements............................................7
Article III PAYMENTS AND ROYALTIES 7
Section 3.01. License Fee.............................................7
Section 3.02. Royalty Payments........................................7
Section 3.03. Reports, Exchange Rates.................................7
Section 3.04. Records and Audits......................................7
Section 3.05. Taxes...................................................8
Section 3.06. Payment Terms...........................................8
Section 3.07. Payment Method..........................................8
Section 3.08. No Assurances...........................................8
Article IV TERM AND TERMINATION 10
Section 4.01. Term...................................................10
Section 4.02. Termination By CollaGenex..............................10
Section 4.03. Termination By Altana..................................10
Section 4.04. Termination Upon Certain Events........................10
Section 4.05. Remedies...............................................10
Section 4.06. Effect of Termination..................................10
Article V COMMERCIALIZATION OF THE PRODUCT 11
Section 5.01. CollaGenex's Obligations...............................11
Article VI MANUFACTURE AND SUPPLY 12
Section 6.01. Agreement to Supply Products...........................12
Section 6.02. Quality Assurance......................................12
Section 6.03. Altana's Duties........................................12
Section 6.04. Failure to Supply......................................13
Article VII PURCHASE AND SALE 13
Section 7.01. Purchase Price and Payment.............................13
Section 7.02. Labeling...............................................13
Section 7.03. Purchase Forms.........................................14
Section 7.04. Forecasts and Orders...................................14
Section 7.05. Confirmation...........................................14
Section 7.06. Delivery...............................................14
i
{PAGE}
TABLE OF CONTENTS
PAGE
Section 7.07. Professional Samples...................................15
Section 7.08. Return of Products.....................................15
Article VIII WARRANTY, REJECTION AND INSPECTIONS OF SHIPMENTS 15
Section 8.01. Altana Warranty........................................15
Section 8.02. Rejection of Product or Professional Samples for
Failure to Conform to Specifications...................15
Section 8.03. CollaGenex Inspections.................................16
Article IX REGULATORY COMPLIANCE 16
Section 9.01. Maintenance of Regulatory Approvals....................16
Section 9.02. Adverse Drug Event Reporting...........................17
Section 9.03. Assistance.............................................17
Section 9.04. Compliance.............................................17
Article X PATENTS AND TRADEMARKS 18
Section 10.01. Maintenance of Patents or Marks.......................18
Section 10.02. Cooperation...........................................18
Section 10.03. Altana to Prosecute Infringement......................18
Section 10.04. Infringement Claimed by Third Parties.................18
Article XI REPRESENTATIONS AND WARRANTIES 19
Section 11.01. Corporate Power.......................................19
Section 11.02. Due Authorization.....................................19
Section 11.03. Binding Obligation....................................19
Section 11.04. Ownership of Patent Rights............................20
Section 11.05. Patent Proceedings....................................20
Section 11.06. Adverse Properties....................................20
Section 11.07. Governmental Approvals................................20
Section 11.08. Protection of the Marks...............................20
Section 11.09. SOP Conformance.......................................20
Section 11.10. Further Actions.......................................20
Section 11.11. Limitation of Liability...............................21
Article XII COVENANTS OF COLLAGENEX 21
Section 12.01. Limitation to the Territory...........................21
Section 12.02. Marketing and Instructional Materials.................21
Section 12.03. Marketing Expenses....................................21
Article XIII PRODUCT RECALL 21
Section 13.01. Product Recalls.......................................21
Section 13.02. Recall Costs..........................................22
Section 13.03. Notification of Complaints............................22
Section 13.04. Notification of Threatened Action.....................23
Article XIV INDEMNIFICATION AND INSURANCE 23
Section 14.01. CollaGenex Indemnified by Altana......................23
ii
{PAGE}
TABLE OF CONTENTS
PAGE
Section 14.02. Altana Indemnified by CollaGenex......................23
Section 14.03. Prompt Notice Required................................23
Section 14.04. Indemnitor May Settle.................................24
Section 14.05. Insurance.............................................24
Article XV DISPUTE RESOLUTION 25
Section 15.01. Disputes..............................................25
Section 15.02. Mediation.............................................25
Section 15.03. Trial Without Jury....................................25
Section 15.04. Performance to Continue...............................25
Section 15.05. Provisional Remedies..................................26
Section 15.06. Determination of Patents and Other Intellectual
Property..............................................26
Article XVI CONFIDENTIALITY 26
Section 16.01. Confidentiality.......................................26
Section 16.02. Publicity Review......................................26
Article XVII MISCELLANEOUS 27
Section 17.01. Non-Solicitation and Non-Compete......................27
Section 17.02. Commercially Reasonable Efforts.......................28
Section 17.03. No Right to Use Names.................................28
Section 17.04. Notices...............................................28
Section 17.05. Section Headings......................................29
Section 17.06. Severability..........................................29
Section 17.07. Entire Agreement/Merger...............................30
Section 17.08. Amendment.............................................30
Section 17.09. Equitable Relief......................................30
Section 17.10. Counterparts..........................................30
Section 17.11. No Waiver of Rights...................................30
Section 17.12. Force Majeure.........................................30
Section 17.13. Further Assurances....................................30
Section 17.14. Assignment............................................30
Section 17.15. Expenses..............................................31
Section 17.16. Binding Effect........................................31
Section 17.17. Governing Law.........................................31
Section 17.18. No Strict Construction................................31
Section 17.19. US Dollars............................................31
Section 17.20. Independent Contractors...............................31
Exhibit A -- Patent Rights...........................................A-1
Exhibit B -- Standard Operating Procedures - Recall..................B-1
Exhibit C -- Specifications..........................................C-1
Exhibit D -- Marks...................................................D-1
Exhibit E -- Standard Operating Procedures - ADE.....................E-1
Exhibit F -- Product Fixed Price Schedule ...........................F-1
Exhibit G -- Standard Altana Production Quantities...................G-1
Exhibit H -- Memorandum..............................................H-1
iii
{PAGE}
AGREEMENT
This Agreement ("Agreement") is made as of May 24, 2002, by and between
Altana Inc., a New York corporation ("Altana"), with its principal place of
business located at 60 Baylis Road, Melville, New York 11747 and CollaGenex
Pharmaceuticals, Inc., a Delaware corporation ("CollaGenex"), with its principal
place of business located at 41 University Drive, Newtown, Pennsylvania 18940.
Altana and CollaGenex are sometimes referred to collectively herein as the
"Parties" and individually as a "Party."
WHEREAS, Altana licenses certain proprietary information, intellectual
property, Patents Rights (as defined below) and Know-How (as defined below), and
possesses manufacturing capabilities for the Product (as defined below), and
subject to the terms of this Agreement, Altana desires to grant to CollaGenex an
exclusive sublicense to market and sell the Product for use in the Territory (as
defined below); and
WHEREAS, CollaGenex desires to obtain from Altana an exclusive sublicense
to advertise, promote, market, distribute, detail and sell the Products.
NOW, THEREFORE, in consideration of the mutual promises, covenants and
agreements hereinafter set forth, the Parties mutually agree to be legally bound
|
End of Preview |
Home Intelligence Services Subscriptions News About Us